Related Experiment Video
Updated: Dec 31, 2025
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Antithrombotic therapy in patients with atrial fibrillation and coronary artery disease
Abdelmoniem Moustafa1, Mohammad Ruzieh1, Ehab Eltahawy1
1Department of Internal Medicine and Cardiology, University of Toledo Medical Center, Toledo, Ohio, USA.
Insights
Omitting aspirin from triple oral antithrombotic therapy (TT) maintains protection against major adverse cardiovascular and cerebrovascular events while significantly reducing bleeding risk. Direct oral anticoagulants show a favorable safety profile compared to vitamin K antagonists in combination therapies.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Atrial fibrillation and coronary artery disease frequently coexist, requiring combined oral anticoagulation and dual antiplatelet therapy.
- Triple oral antithrombotic therapy (TT) reduces ischemic events but increases bleeding risk.
- Current research explores optimizing antithrombotic strategies for these high-risk patients.
Purpose of the Study:
- To evaluate the efficacy and safety of modified triple oral antithrombotic therapy (TT) regimens.
- To compare the outcomes of omitting aspirin versus standard TT.
- To assess the safety profile of direct oral anticoagulants (DOACs) in combination with antiplatelet agents.
Main Methods:
- Review of existing evidence and clinical studies on TT regimens.
- Analysis of major adverse cardiac and cerebrovascular events (MACCE) rates.
- Assessment of bleeding event rates in different TT strategies.
- Comparison of DOACs versus vitamin K antagonists in combination with antiplatelet therapy.
Main Results:
- Omission of aspirin from TT demonstrates comparable efficacy in preventing MACCE.
- Significantly lower bleeding events observed when aspirin is omitted from TT.
- Initial studies suggest DOACs have a more favorable safety profile than vitamin K antagonists when combined with antiplatelet agents.
Conclusions:
- Modified TT regimens, particularly aspirin omission, offer a potentially safer alternative for patients with atrial fibrillation and coronary artery disease.
- DOACs represent a promising option for antithrombotic therapy in this patient population due to their safety profile.
- Further research is warranted to establish optimal antithrombotic strategies balancing efficacy and safety.
Abstract:
Atrial fibrillation and coronary artery disease are commonly coexisting conditions that necessitate the use of an oral anticoagulant as well as dual antiplatelet therapy. Commonly referred to as triple oral antithrombotic therapy (TT), this helps prevent ischemic stroke and myocardial infarction but comes at the expense of an increased risk of bleeding. There is a growing body of evidence that the omission of aspirin from TT has the same preventive efficacy in terms of major adverse cardiacvascular and cerebrovascular events (MACCE) with significantly lower bleeding events. The combination of antiplatelet agents and direct oral anticoagulants (DOAC) is a matter of ongoing research. However, initial studies showed favorable safety profile of DOAC over vitamin K antagonist in combination with antiplatelet agents.
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:29Venous Thrombosis III: Interprofessional Care
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:26Angina IV: Management
01:26Atherosclerosis III: Management